Global coalition to accelerate COVID-19 clinical research in resource-limited settings

摘要

MEB and PH are principal investigators or co-investigators in multiple vaccine development programmes, including for SARS, Middle East respiratory syndrome, and COVID-19 and have grants from the US National Institutes of Health (NIH), for research towards the development of COVID-19 vaccine. PC reports grants from Merck and ViiV Healthcare. SC has a patent PCT/IB2011/055209 with royalties paid to Nearmedic Plus for a tuberculosis drug candidate. JF is Director of the Wellcome Trust. AG receives non-financial support from University of Nairobi. DR reports grants from the Bill & Melinda Gates Foundation, the Wellcome Trust, the Governments of Australia, Ireland, Germany, Monaco, Netherlands, Switzerland, Korea, the UK, and the USA, GHIT Japan, EDCTP, UNITAID, and WHO. MT reports personal fees for board membership from Fondation Botnar (not-for-profit), personal fees for member of scientific advisory board from Novartis Institute for Tropical Diseases, personal fees for board membership from Gebert-Rüf Foundation (not-for-profit), personal fees for board chair from R Geigy Foundation (not-for-profit), personal fees for board membership from University Hospital Basel, Switzerland (public hospital), and personal fees for member of University Senate from the University of Neuchatel (public institution). We declare no other competing interests.